Zhengzhou University Henan Cancer Hospital (ZUHCH) and Proteomedix enter into a cooperation to clinically validate biomarker tests and bioinformatics for prostate cancer diagnostics
Beijing, CN, Henan, CN and Zurich-Schlieren, CH, January 14, 2021. Henan Cancer Hospital and Proteomedix, the Swiss cancer diagnostics company announce today a strategic partnership to validate the Proclarix® prostate cancer diagnostics test in the local population and further develop comprehensive solutions for patient management in prostate cancer diagnostics.
The leading cancer center in central China will partner with Proteomedix on a prospective study to assess the effectiveness of biomarker-based triage of patients with elevated levels or prostate specific antigen that are suspicious for clinically significant prostate cancer.
Professor Youlin Qiao, Chinese Academy of Medical Sciences Peking Union Medical College and Zhengzhou University Henan Cancer Hospital said: ”Prostate cancer is a common form of malignant tumor that severely threatens the health of men. There are 115,426 new cases of prostate cancer in China each year, and over 51,094 deaths due to the disease. It is the most common cancer amongst men from the ages of 55 onwards, it is also the third deadliest cancer in this age group. For this reason, prostate cancer diagnosis and effective patient management has the potential to significantly reduce the incidence of aggressive prostate cancer and reducing the burden of the disease.”
Professor Qiao said further: ”The goal of the partnership includes the assessment of novel biomarkers and their clinical application to prostate cancer prevention with the goal to improve current patient management in prostate cancer screening and prevention. In the longer term it is hoped that this effort will also help advance our understanding of mechanisms of the disease and potentially drug action.”
”Partnering with this renowned institution in China brings a wealth of clinical expertise to us that will advance the translation of biomarker-development and support the adoption of our novel Proclarix test and risks core into clinical practice” said Ralph Schiess, Chief Scientific Officer, Proteomedix.